Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.82 (+1.51%) Nasdaq
16,735.02 -2.08 (-0.01%) Bitcoin USD
69,163.23 +1,672.12 (+2.48%) CMC Crypto 200
1,486.99 +19.05 (+1.30%)
Merck & Co., Inc. (6MKD.XC)
| Previous close | 121.00 |
| Open | 121.00 |
| Bid | 115.20 x N/A |
| Ask | 116.00 x N/A |
| Day's range | 121.00 - 121.00 |
| 52-week range | 92.80 - 121.20 |
| Volume | |
| Avg. volume | 2 |
| Market cap | 306.47B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 145.78 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (2.34%) |
| Ex-dividend date | 17 Jun 2024 |
| 1y target est | N/A |
- Business Wire
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee
- Business Wire
Merck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
- Business Wire
Merck Announces Third-Quarter 2024 Dividend
RAHWAY, N.J., May 28, 2024--Merck Announces Third-Quarter 2024 Dividend
